← Browse by Condition
Medical Condition

anca associated vasculitis

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for anca associated vasculitis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — anca associated vasculitis Clinical Trials

How many clinical trials are currently recruiting for anca associated vasculitis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for anca associated vasculitis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for anca associated vasculitis?
anca associated vasculitis research spans Phase 1 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a anca associated vasculitis clinical trial?
Eligibility criteria for anca associated vasculitis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 3
1
Top Sponsors
Lingli Dong 1 trial
Nanjing University School of Medicine 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial

Recruiting Clinical Trials

NCT06277427
Recruiting
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Enrollment
24 pts
Location
China
Sponsor
Lingli Dong
View Trial →
NCT06285279 Phase 1
Recruiting
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Enrollment
24 pts
Location
China
Sponsor
Nanjing University School of M...
View Trial →
NCT05946564 Phase 3
Recruiting
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
Enrollment
126 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →

Related Conditions

lupus nephritis (2) membranous nephropathy pla2r induced (1) igg4 related diseases (1) rapidly progressive glomerulonephritis (1) crescentic glomerulonephritis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology